On April 8, 2024, Seres Therapeutics, Inc announced that it has held its annual general meeting of shareholders on April 4, 2024, and declared voting results. Accordingly, a stockholder proposal on simple majority vote from Kenneth Steiner was approved by the shareholders of the Company.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.115 USD | +4.21% | +20.97% | -20.36% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.36% | 162M | |
+18.66% | 123B | |
+14.84% | 107B | |
-3.85% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-12.04% | 16.23B | |
+2.04% | 13.43B | |
+24.34% | 11.32B |
- Stock Market
- Equities
- MCRB Stock
- News Seres Therapeutics, Inc.
- Declaration of Voting Results by Seres Therapeutics